Business Context and Reporting Period
This Form 8-K filing by Energy Vault Holdings, Inc. (NYSE: NRGV) is dated September 13, 2024. The report addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance issue. The specific financial metric triggering the notice is the Company's stock price performance: the average closing price of the Common Stock was less than $1.00 over a consecutive 30 trading-day period.
Material Changes
The material event reported is the receipt of a notice from the NYSE on September 13, 2024, stating the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual due to the low stock price. This notice does not result in immediate delisting.
Outlook, Management Commentary, and Risks
- Cure Plan: The Company intends to notify the NYSE by September 27, 2024, of its plan to cure the deficiency. It has a six-month cure period to regain compliance.
- Compliance Criteria: To regain compliance, the Company must achieve a closing share price of at least $1.00 and an average closing share price of at least $1.00 over a 30 trading-day period ending on the last trading day of any calendar month within the cure period.
- Alternatives: The Company may consider alternatives requiring stockholder approval, such as a reverse stock split, to be voted on at the next annual meeting if necessary.
- Risks: The filing highlights the risk of failing to regain compliance within the cure period, which could lead to delisting. It also references broader risk factors detailed in the Company's 2023 Form 10-K and Q2 2024 Form 10-Q.
Investor Verification Checklist
- Verify the current trading price and 30-day average of NRGV stock to assess the likelihood of meeting the $1.00 threshold within the six-month cure period.
- Monitor upcoming announcements regarding the Company's specific cure plan (e.g., reverse stock split) and the timeline for stockholder approval.
- Review the Company's most recent Form 10-Q and Form 10-K for underlying financial health and liquidity constraints that may impact stock price recovery.
- Confirm the date of the next annual meeting of stockholders to understand the deadline for potential corporate actions requiring approval.